Norcantharidin ameliorates estrogen deficient-mediated bone loss by attenuating the activation of extracellular signal-regulated kinase/ROS/NLRP3 inflammasome signaling

• Published in: Frontiers in pharmacology Vol. 13; p. 1019478
• Main Authors: Yang, Guang, Xu, Huikang, Yao, Minjun, Yan, Shigui, Wu, Mengrui, Zhou, Chenhe
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 03.11.2022
• Subjects: ERK; NLRP3 inflammasome; norcantharidin; osteoclast; osteoporosis; Pharmacology; ROS

Osteoporosis, characterized by reduced bone mass, aberrant bone architecture, and elevated bone fragility, is driven by a disruption of bone homeostasis between bone resorption and bone formation. However, up to now, no drugs are perfect for osteoporosis treatment due to different defects. In this s...